PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Discuss various Doctor of Pharmacy Knowledge based topics
#660
According to results presented at the Heart Failure Society of America Annual Scientific Meeting, dose reduction occurred in 42% of the valsartan/sacubitril group and 43% of the enalapril group during the course of the study. Hypotension was the most cited reason for dose reduction in the valsartan/sacubitril group and cough in the enalapril group. Dose reduction was more common in patients who were older, sicker, had higher levels of serum creatinine and NT-proBNP at baseline, and had an implantable cardioverter defibrillator or cardiac resynchronization therapy device, according to Orly Vardeny, PharmD, MS, from the University of Wisconsin School of Pharmacy.

http://www.healio.com/cardiology/hf-tra ... ower-doses
Similar Topics
Topics Statistics Last post
0 Replies 
473 Views
by rahmatulla.syed
17 Jan 2018, 18:59
0 Replies 
1432 Views
by Admin
23 Mar 2017, 17:00
Drug Compatibility Chart
by Admin  - 29 Jun 2017, 18:07  - In: Pharmaceutical Care
0 Replies 
1276 Views
by Admin
29 Jun 2017, 18:07
Drug profile Format- Example
by Admin  - 04 Dec 2018, 10:59  - In: Pharm D Topics
0 Replies 
1185 Views
by Admin
04 Dec 2018, 10:59
0 Replies 
498 Views
by Admin
27 Jul 2018, 09:57

Tags

Researchers at the Koch Institute have created a b[…]

AI (Artificial Intelligence) and ML (Machine Learn[…]

Q: When is an FDA Form 483 issued? A: An FDA Form[…]

Pre-clinical pharmacology plays a vital role in th[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES